Neural Regeneration Research ›› 2021, Vol. 16 ›› Issue (11): 2215-2216.doi: 10.4103/1673-5374.310688

Previous Articles     Next Articles

Glycans to improve efficacy and solubility of protein aggregation inhibitors

Ashim Paul, Daniel Segal, Elsa Zacco   

  1. Department of Molecular Microbiology and Biotechnology, Shmunis School of Biomedicine and Cancer Research, Tel Aviv University, Ramat Aviv, Tel Aviv 6997801, Israel (Paul A, Segal D)
    RNA Central Lab, Center for Human Technologies, Istituto Italiano di Tecnologia, 16152 Genova, Italy (Zacco E) 
  • Online:2021-11-15 Published:2021-04-13
  • Contact: Elsa Zacco, PhD, elsa.zacco@iit.it.
  • Supported by:
    The present work was partially supported by the Israel Ministry of Science and the Alliance Family Trust (to DS). AP is recipient of a fellowship from the Aufzien Family Center for the Prevention and Treatment of Parkinson’s Disease (APPD). EZ has received funding from the MINDED fellowship of the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 754490. 

Abstract: Misfolding and subsequent aberrant self-assembly of certain proteins into toxic amyloid deposits are hallmarks of various diseases, most notably neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (Chiti and Dobson, 2017). Aromatic residues in amyloidogenic proteins have been shown to be key factors in protein oligomerization and fibrilization, mostly driven by π-π interactions. Together with aromaticity, post-translational modifications can greatly affect a protein’s solubility and conformation and, as a consequence, its propensity to aggregate. Among post-translational modifications, this perspective focuses on protein glycosylation, the decoration of a protein with carbohydrate motifs, its effect on amyloid formation and its employment in the inhibition of protein aggregation.